Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy.
Recent studies have reported weight gain in virologically-suppressed persons living with HIV (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)-based regimens. In this study, we investigated whether weight gain differs among treatment-naïve PLWH starting INSTI-based regimens compared to other ART regimens. Adult, treatment-naïve PLWH in the Vanderbilt Comprehensive Care Clinic cohort initiating INSTI, protease inhibitor (PI), and non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART between January 2007 and June 2016 were included. We used multivariable linear mixed effects models to generate marginal predictions of weights over time, adjusting for baseline clinical and demographic characteristics. We used restricted cubic splines to relax linearity assumptions and bootstrapping to generate 95% confidence intervals. Among 1,152 ART-naive PLWH, 356 initiated INSTI-based regimens (135 dolutegravir, 157 elvitegravir and 64 raltegravir), 86% were male, and 49% were white. At ART initiation median age was 35 years, BMI was 25.1 kg/m2, and CD4+ T-cell count was 318 cells/mm3. Virologic suppression at 18-months was similar between different ART classes. At all examined study time points, weight gain was highest among PLWH starting dolutegravir. At 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTI (p<0.05), and 0.5 kg for elvitegravir (p<0.05). PLWH starting dolutegravir also gained more weight at 18 months compared to raltegravir (3.4 kg) and PI (4.1 kg), though these differences were not statistically significant. Treatment-naïve PLWH starting dolutegravir-based regimens gained significantly more weight at 18 months than those starting NNRTI-based and elvitegravir-based regimens.